You are here

Cancer Res DOI:10.1158/0008-5472.CAN-17-1701

Genomic activation of PPARG reveals a candidate therapeutic axis in bladder cancer.

Publication TypeJournal Article
Year of Publication2017
AuthorsGoldstein, JT, Berger, AC, Shih, J, Duke, FF, Furst, L, Kwiatkowski, DJ, Cherniack, AD, Meyerson, M, Strathdee, CA
JournalCancer Res
Date Published2017 Sep 18
ISSN1538-7445
Abstract

The PPARG gene encoding the nuclear receptor PPAR-gamma is activated in bladder cancer, either directly by gene amplification or mutation, or indirectly by mutation of the RXRA gene which encodes the heterodimeric partner of PPAR-gamma. Here we show that activating alterations of PPARG or RXRA lead to a specific gene expression signature in bladder cancers. Reducing PPARG activity, whether by pharmacologic inhibition or genetic ablation, inhibited proliferation of PPARG-activated bladder cancer cells. Our results offer a preclinical proof of concept for PPARG as a candidate therapeutic target in bladder cancer.

DOI10.1158/0008-5472.CAN-17-1701
Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/28923856?dopt=Abstract

Alternate JournalCancer Res.
PubMed ID28923856
Grant ListR35 CA197568 / CA / NCI NIH HHS / United States